Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 7;171(3):344–354. doi: 10.1111/bjh.13582

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Overall survival (OS) according to minimal residual disease (MRD) status and response (pooled across VTD and VTDC arms). Kaplan–Meier analyses of OS in: (A) patients who achieved CR ^flc, ≥VGPR but excluding the CR ^flc patients, or <VGPR; (B) patients with bone marrow‐confirmed CR who were MRD‐negative or MRD‐positive; (C) MRD‐negative patients who achieved CR ^flc or other responses. CI: confidence interval; CR: complete response; CR ^flc: CR with normalized serum free light chain ratio; HR: hazard ratio; NE: not estimatable; VGPR: very good partial response; VTD, bortezomib‐thalidomide‐dexamethasone; VTDC, bortezomib‐thalidomide‐dexamethasone plus cyclophosphamide.